Replies to post #4850 on GTC Biotherapeutics (fka GTCB)

[floblu14]

>it’s conservative to assume that GTC stands to earn a mid-single-digit royalty on the sales of Protexia.<
Each time I spoke with Tom Newberry at the annual meetings, I mentioned the possibility of franchising the goats and/or GTC's expertise (ala Mickey Dees/Burger King). Such an idea:-)
I've decided to request equity participation/stock options- Should we take a poll - LOL

In regards to Bio-Defense - whatever happened to this??
>GTC BIOTHERAPEUTICS AND USAMRIID TO COOPERATIVELY STUDY ATryn® FOR VIRAL HEMORRHAGIC DISEASES

FRAMINGHAM, MA - October 18, 2004 -- GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that it has signed a two-year cooperative research and development agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID) to evaluate the potential therapeutic application of ATryn® to hemorrhagic diseases resulting from infections of the Ebola and Marburg viruses. Under the CRADA, GTC will supply ATryn®, its recombinant form of human antithrombin, for in vitro and preclinical studies developed by the USAMRIID. USAMRIID will perform all work associated with the live viruses.

"We believe that ATryn® has broad therapeutic potential in situations where antithrombin deficiency may be part of the progression of the disease," stated Geoffrey F. Cox, Ph.D., GTC's Chairman and Chief Executive Officer. "This CRADA allows for further evaluation of ATryn®'s therapeutic potential while GTC continues in discussions with potential commercial development partners."<
http://www.transgenics.com/pressreleases/pr101804.html

[DewDiligence]

PharmAthene presentation on Protexia:

http://www.wsw.com/webcast/rrshq12/pip/

The relevant portion starts at 8:15 into the webcast and lasts approximately 3 minutes.

[DewDiligence]

GTC’s Relationship With PharmAthene

[Added Washington Post article posted by biowatch.]


#msg-4107224 2004 IP license for Protexia
#msg-17826727 IP license expanded to all indications
#msg-22544066 2007 process and purification agreement


#msg-25964817 2008 Washington Post article
#msg-18433447 Protexia program in Alzheimer’s disease
#msg-13565694 Protexia grant from US DoD
#msg-14110344 Protexia grant from NIH
#msg-17587523 Biodefense drug-development timeline

--
What are the economics of the relationship for GTC?

GTC has not disclosed the economic terms of the PharmAthene relationship; however, Dr. Cox did provide some color in reply to a question on GTC’s 4Q06 CC (#msg-17607391). Based on that, I think it’s conservative to assume that GTC stands to earn a mid-single-digit royalty on the sales of Protexia. The PharmAthene relationship could thus generate a non-trivial income stream for GTC, especially if the Protexia program in Alzheimer’s disease were to pan out.